Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
02:47

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

2.1K

Current Updates on Therapeutic Advances in the Management of Cardiovascular Diseases

Nasimudeen R Jabir, Ali Nasir Siddiqui, Chelapram Kandy Firoz

  • 1King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia. shamstabrez1@gmail.com.

Current Pharmaceutical Design
|November 26, 2015
PubMed

Insights

Cardiovascular disease (CVD) mortality is rising globally. This review summarizes current pharmacological treatments like statins and anticoagulants, advocating for further research into rapid and effective CVD therapies.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Cardiovascular disease (CVD) remains the leading cause of death worldwide, despite medical advances.
  • Current CVD treatments can slow disease progression but do not offer a rapid cure.
  • Rising CVD mortality rates necessitate improved therapeutic strategies.

Purpose of the Study:

  • To review current pharmacological agents used in cardiovascular disease (CVD) management.
  • To highlight the mechanisms targeted by existing CVD medications.
  • To advocate for continued research in CVD treatment development.

Main Methods:

  • Literature review of pharmacological agents for cardiovascular disease (CVD).
  • Summary of drug classes including HMG-CoA reductase inhibitors (statins), antihypertensives, thrombolytics, and anticoagulants.
  • Analysis of targeted biochemical and molecular events in CVD management.

Main Results:

  • Current pharmacological agents manage CVD by targeting various biochemical pathways.
  • Statins, antihypertensives, thrombolytics, and anticoagulants are key drug classes in CVD care.
  • Existing treatments aim to prevent or reduce disease progression.

Conclusions:

  • Pharmacological interventions are crucial for managing cardiovascular disease (CVD).
  • Further research is essential to develop more rapid and effective CVD treatments.
  • Advancing CVD therapies can help mitigate fatal complications and reduce mortality.

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.3K
Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.8K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
419
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
557